Insights
Cystic fibrosis-related diabetes mellitus (CFRD) is a common complication of cystic fibrosis (CF). Annual screening via oral glucose tolerance test (OGTT) and insulin treatment are recommended for CFRD management.
Area of Science:
- Endocrinology
- Pulmonology
- Metabolic disorders
Background:
- Cystic fibrosis-related diabetes mellitus (CFRD) is the most prevalent endocrine complication in cystic fibrosis (CF).
- CFRD affects over 50% of CF patients by age 40 and is linked to declining pulmonary function and nutritional status.
- Effective CFRD management improves body weight, lung function, and reduces pulmonary exacerbations.
Purpose of the Study:
- To highlight the clinical significance of CFRD in cystic fibrosis patients.
- To emphasize the importance of annual diabetes screening in CF patients.
- To discuss current and potential treatment strategies for CFRD.
Main Methods:
- Annual screening for CFRD using an oral glucose tolerance test (OGTT) is recommended for CF patients aged 10 and older.
- OGTT demonstrates higher sensitivity in detecting CFRD compared to random glucose or hemoglobin A1c tests.
- Insulin is established as the primary treatment for CFRD.
Main Results:
- CFRD screening via OGTT is crucial due to its high prevalence and impact on CF progression.
- Early detection and treatment of CFRD correlate with improved clinical outcomes in CF patients.
- Insulin therapy is the recommended first-line treatment for CFRD.
Conclusions:
- Annual OGTT screening is vital for early CFRD detection in CF patients.
- Insulin is the preferred treatment for CFRD, with ongoing research into other modalities.
- Managing CFRD is essential for improving the overall health and prognosis of individuals with CF.
Abstract:
Cystic fibrosis-related diabetes mellitus (CFRD) is the most common endocrine complication of cystic fibrosis (CF), affecting more than 50% of patients by the 4th decade of life. CFRD is often preceded by worsening pulmonary status and nutritional decline. Treatment of CFRD is associated with improvements in body weight and pulmonary function and a reduction in pulmonary exacerbations. Because of the clinical significance of CFRD, diabetes screening with an oral glucose tolerance test (OGTT) is recommended annually for all patients with CF starting at age 10 years. The OGTT detects CFRD with greater sensitivity than random glucose or hemoglobin A1c testing. The first-line treatment for CFRD is insulin. The use of other treatments such as oral medications remains under study. [Pediatr Ann. 2016;45(9):e321-e326.].
More Related Videos
Related Concept Videos
01:23Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
01:24Cystic Fibrosis: Management
Sinus disease and chronic...
01:20Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
01:22Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:22Diabetes Mellitus: Type 2 and Gestational
01:27Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes: